reports
American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 F...
American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 Financial Results SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “company”) today reported financial results for its fourth quarter and year ended December 31, 2025. Fourth Quarter Highlights Net income available to common stockholders of $3.1 million and $55.6 million for the three months and year ended December 31, 2025, respectively, or $0.05 and $0.92 per diluted share, respectively.FFO of $0.47 and $2.00 per diluted share for the three months and year ended December 3...
Piedmont Announces Promotion of Alex Valente to Co – Chief Operating O...
Piedmont Announces Promotion of Alex Valente to Co – Chief Operating Officer Atlanta, GA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust (the “Company” or “Piedmont”) (NYSE: PDM) announced today that it has promoted Alex Valente to Co- Chief Operating Officer, working alongside George M. Wells, to oversee all property management and asset management areas of the Company. Mr. Valente, who has most recently served as Executive Vice-President of Piedmont’s Southeast Region, has been with the Company for almost 20 years and has been responsible for leasing, asset management, construc...
American Assets Trust, Inc. Releases Tax Status of 2025 Distributions
American Assets Trust, Inc. Releases Tax Status of 2025 Distributions SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the tax treatment of its 2025 dividend distributions as follows: Security Descriptions: Common StockCUSIP: 024013104Ticker Symbol: AAT Record DatePayable DateTotal Distribution Per ShareAllocable to 2025Taxable Ordinary DividendLT Capital GainUnrecaptured Sec. 1250 GainSection 199A DividendsReturn of Capital03/06/2503/20/25$0.340$0.340$0.140480$0.059651$0.042897$0.140480$0.13986906/05/2506/19/25$0.340$0....
PIEDMONT REALTY TRUST ANNOUNCES TAX TREATMENT OF 2025 DIVIDENDS
PIEDMONT REALTY TRUST ANNOUNCES TAX TREATMENT OF 2025 DIVIDENDS Atlanta, GA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust (NYSE: PDM) (“Piedmont”), a real estate investment trust (REIT), announced today the tax treatment of its 2025 common stock dividends as described below. Stockholders are encouraged to consult with their personal tax advisors as to their specific tax treatment of Piedmont dividends. Record DatePaid DateDividend per ShareOrdinary DividendsQualified DividendCapital GainsUnrecaptured Section 1250 Nondividend DistributionsSection 199A Dividend RateNov 22, 2024Ja...
Piedmont Realty Trust, Inc. to Report Fourth Quarter and Annual 2025 F...
Piedmont Realty Trust, Inc. to Report Fourth Quarter and Annual 2025 Financial Results Atlanta, GA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust (NYSE: PDM) announced today that the Company will release its fourth quarter and annual financial results on Wednesday, February 11, 2026, after the close of trading on the New York Stock Exchange. A conference call is scheduled for Thursday, February 12, 2026, at 9:00 a.m. ET and will be broadcast live in listen-only mode on the company’s investor relations website. During the conference call, the Company’s management team will review...
Piedmont Realty Trust, Inc. Leases 2.5 million Square Feet during 2025
Piedmont Realty Trust, Inc. Leases 2.5 million Square Feet during 2025 Signs 679,000 SF of Leases During Fourth Quarter Atlanta, GA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust, Inc. ("Piedmont” or “the Company") (NYSE:PDM), an owner of Class A office properties located primarily in the Sunbelt, announced today, that the Company leased 2.5 million square feet, or approximately 16% of its portfolio, during 2025, including 679,000 square feet of leases signed during the fourth quarter. Approximately two-thirds of the Company’s 2025 leasing related to new tenants, and almost ha...
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcar...
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Expects Operating Expenses of Between $210 Million and $2...
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025...
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2025 earnings in a press release to be issued after the market closes on Tuesday, February 3, 2026. Senior management will hold a conference call for its fourth quarter and year-end 2025 earnings on Wednesday, February 4, 2026 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 a...
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare...
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025. The company’s presentation and participation in a fireside chat will begin at 2:15 p.m. PT/5:15 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be ...
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientif...
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes – Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific ...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equ...
Piedmont Realty Trust, Inc. Signs over 475,000 SF of Leases Fourth Qua...
Piedmont Realty Trust, Inc. Signs over 475,000 SF of Leases Fourth Quarter-to-Date Bringing Year to Date Leasing to Approximately 2.3 million Square Feet Atlanta, GA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Piedmont Realty Trust, Inc. ("Piedmont” or “the Company") (NYSE:PDM), an owner of Class A office properties located primarily in the Sunbelt, announced today, that the Company is participating in this week’s Nareit's REITworld: 2025 Annual Conference in Dallas, TX. The Company has completed over 475,000 square feet of leasing thus far in the fourth quarter, with approximately 275,000 square ...
Cincinnati Financial Corp: 1 director
A director at Cincinnati Financial Corp maiden bought 140 shares at 163.770USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- MarketLine Department
W. R. Berkley Corporation - Mergers & Acquisitions (M&A), Partnerships...
Summary Marketline's W. R. Berkley Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by W. R. Berkley Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances...
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment ...
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia – Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for ...
PIEDMONT REALTY TRUST ANNOUNCES RESULTS OF TENDER OFFER FOR ANY AND AL...
PIEDMONT REALTY TRUST ANNOUNCES RESULTS OF TENDER OFFER FOR ANY AND ALL OF ITS OUTSTANDING 9.250% SENIOR NOTES DUE 2028 Atlanta, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Piedmont Realty Trust, Inc. (“Piedmont” or the “Company”) (NYSE: PDM), today announced the results, as of 5:00 p.m., New York City time, on November 19, 2025 (the “Expiration Time”), of the previously announced cash tender offer of its operating partnership, Piedmont Operating Partnership, LP (the “Operating Partnership”), to purchase any and all of its outstanding 9.250% senior notes due 2028 (the “notes”). The cash tender offe...
PIEDMONT REALTY TRUST ANNOUNCES PRICING OF CASH TENDER OFFER FOR ANY A...
PIEDMONT REALTY TRUST ANNOUNCES PRICING OF CASH TENDER OFFER FOR ANY AND ALL OF ITS OUTSTANDING 9.250% SENIOR NOTES DUE 2028 Atlanta, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Piedmont Realty Trust, Inc. (“Piedmont” or the “Company”) (NYSE: PDM) today announced the pricing of the cash tender offer to purchase any and all of its outstanding 9.250% senior notes due 2028 (the “notes”) for the consideration described below by its operating partnership, Piedmont Operating Partnership, LP (the “Operating Partnership”). The table below sets forth the applicable Reference Yield and Consideration for the ...
Esperion to Participate in Piper Sandler 37th Annual Healthcare Confer...
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsperion...
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for t...
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for ...
Piedmont Realty Trust Announces Pricing of Senior Notes Offering
Piedmont Realty Trust Announces Pricing of Senior Notes Offering Atlanta, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Piedmont Realty Trust, Inc. (the “Company” or “Piedmont”) (NYSE:PDM) announced today that its operating partnership, Piedmont Operating Partnership, LP (the “Operating Partnership”), has priced an offering of $400 million aggregate principal amount of 5.625% senior notes due 2033 at 99.364% of the principal amount. The offering is expected to close on November 20, 2025, subject to the satisfaction of customary closing conditions. Piedmont intends to use the net proceeds from the of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.